LianBio, a Princeton-based biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, on May 10 announced Yizhe Wang was named chief executive officer and appointed to the board of directors, effective May 17, 2021.
“Yizhe is a strategic leader with decades of experience developing, launching and managing the product lifecycle of transformative drugs in China, the U.S. and Europe,” said Konstantin Poukalov, managing director, Perceptive Advisors and executive chairman, LianBio. “With his proven leadership guiding late-stage assets to market in China, LianBio is well positioned for our next phase of growth as we continue to advance our pipeline and partner with leading global biopharmaceutical companies to expand their reach into China and other Asian markets.”
Wang played a key role in the development, approval and commercialization of more than 25 innovative medicines. His past experience spans commercial, R&D and strategic leadership roles at Eli Lilly and GlaxoSmithKline (GSK), bringing expertise in accelerating drug development and executing commercial launches to LianBio.
“I am honored to join LianBio to scale the company’s next-generation approach to sourcing, developing and commercializing innovative drugs in the region,” said Wang. “As LianBio continues to advance a portfolio of world-class programs across therapeutic areas, I look forward to partnering with the founding team to address the medical needs of patients in China and throughout Asia.”
Prior to LianBio, Wang was at Eli Lilly where he most recently served as global brand development Leader, Lilly Oncology. In 2020, he served as global platform lead for anti-COVID Therapy, Lilly Research Lab, where he led a new operating model integrating discovery, development and launch resulting in the EUA of bamlanivimab.
Wang was previously senior vice president, head of BioMedicines and Oncology Businesses, Lilly China, where he was a member of the Global Oncology and Biomedicines Business Unit lead teams, and China Executive Committee. In this role, he oversaw a 1,000-person organization, delivered double-digit sales growth and launched multiple new products, including Tyvyt, Elunate, Taltz and Olumiant. Prior to Eli Lilly, Wang was at GSK for 15 years where he held product and commercial strategy roles of increasing responsibility in the U.S. (2003-2012), U.K. (2012-2014) and China (2014-2018), ultimately serving as head of GSK China Pharmaceuticals’ Respiratory Business Unit. Earlier in his career, he was a researcher at Bristol Myers Squibb.